Piper Sandler Maintains Neutral on RxSight, Lowers Price Target to $8

Benzinga · 2d ago
Piper Sandler analyst Adam Maeder maintains RxSight (NASDAQ:RXST) with a Neutral and lowers the price target from $10 to $8.